Genmab — Oktober 2018
-
Jeg ved ikke rigtig med den 'forsinkelse'. Allerførste patient blev behandlet februar 15, men studiet først officielt rekrutterende fra april 15. Rekruttering afsluttet august 17. Vel viden, at det er umuligt at regne ud, så vil et skøn over gennemsnitlig behandlingstid august 17 være max. 15 mdr (udbredelsen til mange lande tog lang tid). der er så gået 13 siden. Så en median follow up på måske 28 mdr. cirka. Interval 13-43 mdr. Nu ved vi ikke, hvor mange events der skal til,
-
small downtrend channel http://www.proinvestor.com/index.php?p=debat_1&postid=76310
-
...yes, et større shortingangreb fra AB
-
(just kidding)
-
Bryan Garnier
Victor Floc’h
05/10/2018
Genmab | It’s Time to GEN up on ofa!
Following J&J's decision to discontinue two clinical trials evaluating Darzalex with I/O therapies in lung cancer and multiple myeloma last May, Genmab shares dropped 20% and have yet to recover. In our view, the market is overly conservative and does not fully value either Darzalex or ofatumumab. -
New trial: A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03697629?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=10%2F05%2F2018&rank=1
er der en fredagsnyhed på vej ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind